ASX - Delayed Quote AUD

Chimeric Therapeutics Limited (CHM.AX)

0.0050
0.0000
(0.00%)
At close: 3:59:39 PM GMT+10
Currency in AUD All numbers in thousands
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Operating Expense
20,658.2250
21,019.7760
29,487.1990
17,189.6990
15,691.0170
Operating Income
-20,658.2250
-21,019.7760
-29,487.1990
-17,189.6990
-15,691.0170
Net Non Operating Interest Income Expense
13.3710
-210.4960
-746.2800
-627.1500
-3.2310
Other Income Expense
3,033.6060
8,710.1000
4,825.9150
2,082.1690
-263.7900
Pretax Income
-17,611.2480
-12,520.1720
-25,407.5640
-14,459.9520
-15,113.7110
Tax Provision
220.4850
9.6770
92.8200
163.7200
0
Net Income Common Stockholders
-17,831.7330
-12,529.8490
-25,500.3840
-14,623.6720
-15,113.7110
Basic EPS
-0.02
-0.02
-0.06
-0.04
-0.07
Diluted EPS
-0.02
-0.02
-0.06
-0.04
-0.07
Basic Average Shares
965,283.3640
730,421.5000
454,906.7670
377,929.0640
198,152.5420
Diluted Average Shares
965,283.3640
730,421.5000
454,906.7670
377,929.0640
198,152.5420
Net Income from Continuing & Discontinued Operation
-17,831.7330
-12,529.8490
-25,500.3840
-14,623.6720
-15,113.7110
Normalized Income
-17,831.0372
-12,529.1532
-25,498.6704
-14,622.2265
-15,113.7110
Interest Income
98.8300
121.3150
27.5650
12.9770
2.6460
Interest Expense
85.4590
331.8110
773.8450
640.1270
5.8770
Net Interest Income
13.3710
-210.4960
-746.2800
-627.1500
-3.2310
EBIT
-17,525.7890
-12,188.3610
-24,633.7190
-13,819.8250
-15,107.8340
EBITDA
-17,525.7890
-11,182.2320
-23,668.3680
-12,870.0630
-14,260.8740
Reconciled Depreciation
949.7620
1,006.1290
965.3510
949.7620
846.9600
Net Income from Continuing Operation Net Minority Interest
-17,831.7330
-12,529.8490
-25,500.3840
-14,623.6720
-15,113.7110
Total Unusual Items Excluding Goodwill
-0.9940
-0.9940
-2.4480
-2.0650
--
Total Unusual Items
-0.9940
-0.9940
-2.4480
-2.0650
--
Normalized EBITDA
-17,524.7950
-11,181.2380
-23,665.9200
-12,867.9980
-14,260.8740
Tax Rate for Calcs
0.0003
0.0003
0.0003
0.0003
0
Tax Effect of Unusual Items
-0.2982
-0.2982
-0.7344
-0.6195
0
6/30/2021 - 1/17/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers